Page 37 - 2019_11 Resto del Mondo-web
P. 37

Ph-like ALL
Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1- PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013;31(25):e413- 416.
69. Kobayashi K, Miyagawa N, Mitsui K, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediatr Blood Cancer. 2015;62(6):1058-1060.
70. Zhang G, Zhang Y, Wu J, Chen Y, Ma Z. Acute lymphoblastic leukemia patient with variant ATF7IP/PDGFRB fusion and favor- able response to tyrosine kinase inhibitor treatment: a case report. Am J Case Rep. 2017;18:1204-1208.
71. Perwein T, Strehl S, Konig M, et al. Imatinib- induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2016;101(8):e332- 335.
72. Frech M, Jehn LB, Stabla K, et al. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2017;102(4):e160-e162.
73. Zhang Y, Gao Y, Zhang H, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood. 2018;131(20):2256-2261.
74. Yeung DT, Moulton DJ, Heatley SL, et al. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treat- ment. Leukemia. 2015;29(1):230-232.
75. Zimmermannova O, Doktorova E, Stuchly J, et al. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene. 2017;36(43):5985-5994.
76. Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the ran- domized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174-184.
77. Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123(10):1470- 1478.
78. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allo- geneic bone marrow transplantation is an important determinant of successful out- come for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92(11):4072-4079.
79. Sramkova L, Muzikova K, Fronkova E, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell trans- plantation predicts extremely poor progno- sis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;48 (1):93-100.
80. Sutton R, Shaw PJ, Venn NC, et al. Persistent MRD before and after allogeneic BMT pre- dicts relapse in children with acute lym- phoblastic leukaemia. Br J Haematol. 2015;168(3):395-404.
81. Ifversen M, Turkiewicz D, Marquart HV, et al. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience. Br J Haematol. 2019;184(6):982-993.
82. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lym-
phoblastic leukemia. Blood. 2018;131(14):
1522-1531
83. Gokbuget N, Dombret H, Giebel S, et al.
Minimal residual disease level predicts out- come in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019;24(1):337-348.
84. Zhang R, Lu X, Wang H, et al. Idarubicin- intensified hematopoietic cell transplanta- tion improves relapse and survival of high- risk acute leukemia patients with minimal residual disease. Biol Blood Marrow Transplant. 2019;25(1):47-55.
85. Ding YY, Stern JW, Jubelirer TF, et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure. Haematologica. 2018;103(9):e427-e431.
86. Mori Y, Ikeda K, Inomata T, et al. Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant. 2016;51(12):1584-1587.
87. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft- versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062-2068.
88. Yeshurun M, Weisdorf D, Rowe JM, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3(4):670-680.
89. Kim SK, Knight DA, Jones LR, et al. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes Dev. 2018;32(11-12):849- 864.
90. Churchman ML, Evans K, Richmond J, et al. Synergism of FAK and tyrosine kinase inhi- bition in Ph(+) B-ALL. JCI Insight. 2016;1(4).
91. Kurmasheva RT, Gorlick R, Kolb EA, et al. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pedi- atric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2017;64(4).
92. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adoles- cents with B-cell precursor acute lym- phoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
93. Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor progno- sis and are candidates for stem cell trans- plantation and targeted therapies. Blood. 2012;120(9):1868-1876.
94. te Kronnie G, Silvestri D, Vendramini E, et al. Philadelphia-like signature in childhood acute lymphoblastic leukemia: the AIEOP experience. Blood. 2013;122(21):353.
95. Bhatt NS, Phelan R, Burke MJ. The role of hematopoietic stem-cell transplantation in first remission in pediatric acute lym- phoblastic leukemia: a narrative review. J Pediatr Rev. 2017;5(2):e10831.
96. Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-nega- tive acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798-809.
97. Sutton R, Venn NC, Law T, et al. A risk score
including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. Br J Haematol. 2018;180(4):550-562.
98. Olsson L, Ivanov Ofverholm I, Noren- Nystrom U, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precur- sor acute lymphoblastic leukaemia is inde- pendent of minimal residual disease stratifi- cation in Nordic Society for Paediatric Haematology and Oncology treatment pro- tocols used between 1992 and 2013. Br J Haematol. 2015;170(6):847-858.
99. Li JF, Dai YT, Lilljebjorn H, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A. 2018;115(50):E11711- E11720.
100.Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
101.Gore L, Locatelli F, Zugmaier G, et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Cancer J. 2018;8(9):80.
102.von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatu- momab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381- 4389.
103. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
104. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-459.
105. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remis- sions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
106.Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
107.Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini- HCVD) with or without blinatumomab ver- sus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome- negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125 (15):2579-2586.
108.MillerKC,Al-KaliA,ShahMV,etal.Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leuk Lymphoma. 2019;60(4):990-999.
109.Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome- negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240-248.
110.Jabbour E, Sasaki K, Ravandi F, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper- CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124 (20):4044-4055.
haematologica | 2019; 104(11)
2143


































































































   35   36   37   38   39